No Data
No Data
No Data
No Data
No Data
Nanjing Pharmaceutical (600713.SH) announced first-quarter results. Net profit of 1.59 yuan increased 6.65% year over year
Nanjing Pharmaceutical (600713.SH) released its report for the first quarter of 2024. The company achieved operating income of 1 during the reporting period...
Zhitong FinanceApr 29 04:07 ET
NanJing Medical Plans to Issue Up to 6 Billion Yuan in Ultra Short-Term Bonds
NanJing Medical's (SHA:600713) plans to issue ultra-short-term bonds worth up to 6 billion yuan, according to a Monday filing with the Shanghai bourse. The bonds shall have an issuance period of up to
MT NewswiresApr 8 04:57 ET
[BT Financial Report Momentary Analysis] Nanjing Pharmaceutical's 2023 Quarterly Report: Asset Growth and Cash Flow Challenges Under Steady Operation
As an important participant in the pharmaceutical distribution industry, Nanjing Pharmaceutical Co., Ltd. (stock code: 600713) directly serves the national medical and health industry. The company's business covers the procurement, warehousing, management and sale of pharmaceuticals and medical equipment, and is supervised by various national departments such as the Ministry of Commerce. Within the industry, Nanjing Pharmaceutical not only actively participated in the activities of industry self-regulatory organizations, but also continued to contribute to the development of the pharmaceutical distribution field. In terms of assets and liabilities, Nanjing Pharmaceutical's 2023 three-quarter report shows that the company's total assets increased from 31,651 billion yuan at the end of the previous year to 33.203 billion yuan, an increase
businesstimes cnJan 30 23:24 ET
Nanjing Pharmaceutical (600713.SH): Application to issue convertible bonds accepted by the Shanghai Stock Exchange
Gelonghui, January 18, 丨 Nanjing Pharmaceutical (600713.SH) announced that on January 17, 2024, the company received the “Notice on Accepting the Application for Issuance of Securities by Nanjing Pharmaceutical Co., Ltd. Shanghai Main Board Listed Company” (Shanghai Stock Exchange) (Shanghai Stock Exchange) [2024] No. 20) issued by the Shanghai Stock Exchange (hereinafter referred to as the “Shanghai Stock Exchange”). The Shanghai Stock Exchange checked the prospectus and related application documents submitted by the company for the issuance of securities by a company listed on the Shanghai Main Board. It believed that the application documents were complete and complied with the legal form, and decided to accept them and review them in accordance with the law.
Gelonghui FinanceJan 18 02:44 ET
Nanjing Pharmaceutical (600713.SH): The company became one of the first companies to join the ESG branch of the China Pharmaceutical Business Association in 2023
On January 15, Ge Longhui Pharmaceutical (600713.SH) said on the investor interactive platform that ESG is a sustainable development concept and corporate evaluation standard that focuses on non-financial factors such as corporate environmental responsibility, social responsibility, and corporate governance. The company became one of the first companies to join the ESG branch of the China Pharmaceutical Business Association in 2023. It will continue to standardize governance, implement the social responsibilities of state-owned listed companies, implement the country's requirements for green development, adhere to green and low-carbon development, and do a good job of energy saving and emission reduction.
Gelonghui FinanceJan 15 02:32 ET
NanJing Pharmaceutical's (SHSE:600713) Five-year Earnings Growth Trails the Notable Shareholder Returns
When you buy and hold a stock for the long term, you definitely want it to provide a positive return. Furthermore, you'd generally like to see the share price rise faster than the market. Unfortunat
Simply Wall StDec 13, 2023 17:17 ET
No Data
No Data